Rayan Mroueh1, Aaro Haapaniemi1, Reidar Grénman2, Jussi Laranne3, Matti Pukkila4, Alhadi Almangush5, Tuula Salo6,7, Antti Mäkitie1. 1. Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Department of Otorhinolaryngology - Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland. 3. Department of Otorhinolaryngology - Head and Neck Surgery, Tampere University Hospital, Tampere, Finland. 4. Department of Otorhinolaryngology - Head and Neck Surgery, Kuopio University Hospital, Kuopio, Finland. 5. Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland. 6. Cancer and Translational Medicine Unit, University of Oulu, Medical Research Unit, Oulu University Hospital. 7. Oral and Maxillofacial Diseases, University of Helsinki, and Haartman Institute, Helsinki, Finland.
Abstract
BACKGROUND: Incidence rates for oral tongue squamous cell carcinoma (SCC) are steadily rising worldwide. METHODS: All patients diagnosed with primary oral tongue SCC at the 5 university hospitals in Finland from 2005 to 2009 were studied. The mean follow-up time was 43 months (median, 54 months; range, 0-111 months). RESULTS: Three hundred sixty patients with primary oral tongue SCC were identified. Treatment with curative intent was provided for 328 patients (91%). The 5-year disease-specific survival (DSS) rates were as follows: stage I 87%; stage II 73%; stage III 69%; and stage IV 51%. The 5-year recurrence-free survival in general has improved from 47% in our previous published series (1995-1999) to 65% in the current series (p < .001). CONCLUSION: The outcome of oral tongue SCC has significantly improved in Finland. However, the relatively high number of disease recurrences in patients with stage I and II disease, when compared with patients with stage III and IV disease, calls for an investigation of new treatment approaches.
BACKGROUND: Incidence rates for oral tongue squamous cell carcinoma (SCC) are steadily rising worldwide. METHODS: All patients diagnosed with primary oral tongue SCC at the 5 university hospitals in Finland from 2005 to 2009 were studied. The mean follow-up time was 43 months (median, 54 months; range, 0-111 months). RESULTS: Three hundred sixty patients with primary oral tongue SCC were identified. Treatment with curative intent was provided for 328 patients (91%). The 5-year disease-specific survival (DSS) rates were as follows: stage I 87%; stage II 73%; stage III 69%; and stage IV 51%. The 5-year recurrence-free survival in general has improved from 47% in our previous published series (1995-1999) to 65% in the current series (p < .001). CONCLUSION: The outcome of oral tongue SCC has significantly improved in Finland. However, the relatively high number of disease recurrences in patients with stage I and II disease, when compared with patients with stage III and IV disease, calls for an investigation of new treatment approaches.
Authors: K Juurikka; A Dufour; K Pehkonen; B Mainoli; P Campioni Rodrigues; N Solis; T Klein; P Nyberg; C M Overall; T Salo; P Åström Journal: Oncogenesis Date: 2021-05-31 Impact factor: 7.485
Authors: Marta Tagliabue; Pietro Belloni; Rita De Berardinis; Sara Gandini; Francesco Chu; Stefano Zorzi; Caterina Fumagalli; Luigi Santoro; Susanna Chiocca; Mohssen Ansarin Journal: Cancer Med Date: 2021-03-24 Impact factor: 4.452
Authors: Alessia Di Rito; Francesco Fiorica; Roberta Carbonara; Francesca Di Pressa; Federica Bertolini; Francesco Mannavola; Frank Lohr; Angela Sardaro; Elisa D'Angelo Journal: Cancers (Basel) Date: 2022-07-29 Impact factor: 6.575
Authors: Amr Elseragy; Ibrahim O Bello; Awais Wahab; Ricardo D Coletta; Antti A Mäkitie; Ilmo Leivo; Alhadi Almangush; Tuula Salo Journal: Head Neck Date: 2022-02-28 Impact factor: 3.821
Authors: Alhadi Almangush; Antti A Mäkitie; Laura K Mäkinen; Joonas H Kauppila; Matti Pukkila; Jaana Hagström; Jussi Laranne; Ylermi Soini; Luiz Paulo Kowalski; Reidar Grénman; Caj Haglund; Ricardo D Coletta; Tuula Salo; Ilmo Leivo Journal: Virchows Arch Date: 2018-07-23 Impact factor: 4.064
Authors: Inger-Heidi Bjerkli; Olav Jetlund; Gunnhild Karevold; Ása Karlsdóttir; Ellen Jaatun; Lars Uhlin-Hansen; Oddveig G Rikardsen; Elin Hadler-Olsen; Sonja E Steigen Journal: PLoS One Date: 2020-01-16 Impact factor: 3.240